Home > News

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data
D&I Policy: a further demonstration of Chiesi's commitment
New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed
The Chiesi Group is on Twitter!
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
World Prematurity Day: Chiesi is at the forefront for preterm babies
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
Italy for Climate: Chiesi at the forefront for the future of Italy
The B Change: the Instant Book by Pharmastar is online
Chiesi Group and Holostem Terapie Avanzate announce transfer of Holoclar® from the Chiesi Group to Holostem
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
Chiesi: “imprese per innovazione” award, Industry 4.0 and Sustainability Special Mentions
Chiesi enters in an exclusive global license agreement with TiumBio to develop innovative molecules for respiratory diseases
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large pharmaceuticals companies and healthcare organizations
Chiesi signs a deal with StartUp Health: first investment in the digital area
Chiesi supports The Third Day exhibition, dedicated to the relationship between man and nature
Global Corporate Development : opening of new offices in Boston
Chiesi Digital Transformation - Digital Safari Workshop with David Orban
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Chiesi certified Top Employer also for 2017
Chiesi is Top Employer again!
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Special Mention to Holoclar at the Italian Galeno Award
COPD indication for Foster pMDI
Double-digit growth and internal expansion for the Chiesi Group